• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

siRNA 靶向治疗胃肠道疾病。

siRNA Targeting and Treatment of Gastrointestinal Diseases.

机构信息

Children's Mercy Kansas City, Kansas City, Missouri, USA.

University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.

出版信息

Clin Transl Sci. 2019 Nov;12(6):573-585. doi: 10.1111/cts.12668. Epub 2019 Aug 5.

DOI:10.1111/cts.12668
PMID:31309709
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6853152/
Abstract

RNA interference via small interfering RNA (siRNA) offers opportunities to precisely target genes that contribute to gastrointestinal (GI) pathologies, such as inflammatory bowel disease, celiac, and esophageal scarring. Delivering the siRNA to the GI tract proves challenging as the harsh environment of the intestines degrades the siRNA before it can reach its target or blocks its entry into its site of action in the cytoplasm. Additionally, the GI tract is large and disease is often localized to a specific site. This review discusses polymer and lipid-based delivery systems for protection and targeting of siRNA therapies to the GI tract to treat local disease.

摘要

通过小干扰 RNA（siRNA）的 RNA 干扰为靶向导致胃肠道（GI）疾病的基因提供了机会，例如炎症性肠病、乳糜泻和食管瘢痕。将 siRNA 递送到胃肠道具有挑战性，因为肠道恶劣的环境会在 siRNA 到达靶标之前使其降解，或阻止其进入细胞质中的作用部位。此外，胃肠道很大，疾病通常局限于特定部位。这篇综述讨论了聚合物和脂质基递药系统，用于保护和靶向 siRNA 疗法到胃肠道以治疗局部疾病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/299b/6853152/78727acff2e3/CTS-12-573-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/299b/6853152/ca6a6698e70d/CTS-12-573-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/299b/6853152/78727acff2e3/CTS-12-573-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/299b/6853152/ca6a6698e70d/CTS-12-573-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/299b/6853152/78727acff2e3/CTS-12-573-g002.jpg

相似文献

1
siRNA Targeting and Treatment of Gastrointestinal Diseases.siRNA 靶向治疗胃肠道疾病。
Clin Transl Sci. 2019 Nov;12(6):573-585. doi: 10.1111/cts.12668. Epub 2019 Aug 5.
2
Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.仿生药物递送材料：探索肺表面活性剂在 siRNA 吸入治疗中的作用。
J Control Release. 2015 Dec 28;220(Pt B):642-50. doi: 10.1016/j.jconrel.2015.09.004. Epub 2015 Sep 10.
3
Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.癌症小鼠模型中体内小干扰RNA递送的评估
Methods Mol Biol. 2016;1402:189-197. doi: 10.1007/978-1-4939-3378-5_15.
4
Nonviral pulmonary delivery of siRNA.非病毒肺部递送 siRNA。
Acc Chem Res. 2012 Jul 17;45(7):961-70. doi: 10.1021/ar200110p. Epub 2011 Sep 9.
5
Budding Alliance of Nanotechnology in RNA Interference Therapeutics.RNA 干扰治疗中的新兴纳米技术联盟。
Curr Pharm Des. 2018;24(23):2632-2643. doi: 10.2174/1381612824666180807113948.
6
Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?纳米颗粒-siRNA：卵巢癌治疗的潜在策略？
Nanomedicine (Lond). 2019 Aug;14(15):2083-2100. doi: 10.2217/nnm-2018-0379. Epub 2019 Aug 1.
7
Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.用于呼吸道 COVID-19 疾病的 RNAi 治疗的纳米颗粒递送平台。
Int J Mol Sci. 2022 Feb 22;23(5):2408. doi: 10.3390/ijms23052408.
8
Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.重新点燃 RNAi 疗法：体内 siRNA 递送的材料设计要求。
Adv Mater. 2019 Dec;31(49):e1903637. doi: 10.1002/adma.201903637. Epub 2019 Sep 30.
9
Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.用于递送基于合成RNA干扰疗法的阳离子液晶纳米颗粒。
Oncotarget. 2017 Jul 18;8(29):48222-48239. doi: 10.18632/oncotarget.18421.
10
A designed recombinant fusion protein for targeted delivery of siRNA to the mouse brain.一种设计用于将 siRNA 靶向递送至小鼠大脑的重组融合蛋白。
J Control Release. 2016 Apr 28;228:120-131. doi: 10.1016/j.jconrel.2016.03.007. Epub 2016 Mar 4.

引用本文的文献

1
Principle, application and challenges of development siRNA-based therapeutics against bacterial and viral infections: a comprehensive review.基于小干扰RNA的抗细菌和病毒感染疗法的原理、应用及发展挑战：综述
Front Microbiol. 2024 Jun 13;15:1393646. doi: 10.3389/fmicb.2024.1393646. eCollection 2024.
2
Emerging molecules, tools, technology, and future of surgical knife in gastroenterology.胃肠病学中新兴的分子、工具、技术及手术刀的未来
World J Gastrointest Surg. 2024 Apr 27;16(4):988-998. doi: 10.4240/wjgs.v16.i4.988.
3
Nanocarriers for delivery of siRNA as gene silencing mediator.

本文引用的文献

1
Positioning biologics and new therapies in the management of inflammatory bowel disease.生物制剂和新疗法在炎症性肠病管理中的定位
Curr Opin Gastroenterol. 2019 Jul;35(4):296-301. doi: 10.1097/MOG.0000000000000546.
2
Re-Engineering RNA Molecules into Therapeutic Agents.将 RNA 分子重建成治疗剂。
Acc Chem Res. 2019 Apr 16;52(4):1036-1047. doi: 10.1021/acs.accounts.8b00650. Epub 2019 Mar 26.
3
Functional features defining the efficacy of cholesterol-conjugated, self-deliverable, chemically modified siRNAs.定义胆固醇共轭、自递送、化学修饰的 siRNA 功效的功能特征。
用于递送作为基因沉默介质的小干扰RNA的纳米载体。
EXCLI J. 2022 Aug 1;21:1028-1052. doi: 10.17179/excli2022-4975. eCollection 2022.
4
Fate of Tableted Freeze-Dried siRNA Lipoplexes in Gastrointestinal Environment.冻干片剂形式的小干扰RNA脂质复合物在胃肠道环境中的命运
Pharmaceutics. 2021 Oct 28;13(11):1807. doi: 10.3390/pharmaceutics13111807.
5
Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease.综述：炎症性肠病中局部肿瘤坏死因子-α抑制作用
Pharmaceutics. 2020 Jun 11;12(6):539. doi: 10.3390/pharmaceutics12060539.
Nucleic Acids Res. 2018 Nov 16;46(20):10905-10916. doi: 10.1093/nar/gky745.
4
Structural basis for the synergy of 4'- and 2'-modifications on siRNA nuclease resistance, thermal stability and RNAi activity.结构基础：4′-和 2′-修饰在 siRNA 核酸酶抗性、热稳定性和 RNAi 活性方面的协同作用。
Nucleic Acids Res. 2018 Sep 19;46(16):8090-8104. doi: 10.1093/nar/gky703.
5
TNFα gene silencing mediated by orally targeted nanoparticles combined with interleukin-22 for synergistic combination therapy of ulcerative colitis.通过口服靶向纳米颗粒介导的 TNFα 基因沉默联合白细胞介素-22 进行协同组合治疗溃疡性结肠炎。
J Control Release. 2018 Oct 10;287:235-246. doi: 10.1016/j.jconrel.2018.08.021. Epub 2018 Aug 11.
6
The proton sponge hypothesis: Fable or fact?质子海绵假说：虚构还是事实？
Eur J Pharm Biopharm. 2018 Aug;129:184-190. doi: 10.1016/j.ejpb.2018.05.034. Epub 2018 May 30.
7
Chemical Modification of the siRNA Seed Region Suppresses Off-Target Effects by Steric Hindrance to Base-Pairing with Targets.小干扰RNA种子区域的化学修饰通过空间位阻抑制与靶标的碱基配对来减少脱靶效应。
ACS Omega. 2017 May 31;2(5):2055-2064. doi: 10.1021/acsomega.7b00291. Epub 2017 May 12.
8
Oral delivery of siRNA lipid nanoparticles: Fate in the GI tract.口服递送 siRNA 脂质纳米粒：在胃肠道中的命运。
Sci Rep. 2018 Feb 1;8(1):2178. doi: 10.1038/s41598-018-20632-6.
9
Eosinophilic Esophagitis in Children and Adults.儿童和成人嗜酸性粒细胞性食管炎
Gastrointest Endosc Clin N Am. 2018 Jan;28(1):59-75. doi: 10.1016/j.giec.2017.07.004.
10
Combination Therapy in Pediatric Inflammatory Bowel Disease: Yes, No, Maybe.儿童炎症性肠病的联合治疗：是，否，或许。
Inflamm Bowel Dis. 2017 Oct;23(10):1774-1776. doi: 10.1097/MIB.0000000000001206.